尽管公司亏损,但Atara Biotherapeutics在2025年第三季度的收益估计仍超出预期,因为其疗法在研究的后期阶段取得了进展. Atara Biotherapeutics beat earnings estimates in Q3 2025 despite a loss, as its lead therapy advanced in late-stage trials.

Atara生物治疗公司报告说,2025年第三季度损失了每股0.32美元,粗略估计损失51美元,收入350万美元。 Atara Biotherapeutics reported a third-quarter 2025 loss of $0.32 per share, beating estimates by $0.51, with $3.5 million in revenue. 该公司的主要治疗方法Tab-cel已在与EBV相关的移植后淋巴增殖性疾病和鼻癌的第三期试验中取得进展. The company’s lead therapy, Tab-cel, advanced in Phase 3 trials for EBV-related post-transplant lymphoproliferative disease and nasopharyngeal carcinoma. 尽管股本和净差值出现负回报,股票略有上升,接近12.23美元,机构投资者持有70.9%的股份。 Despite a negative return on equity and net margin, the stock rose slightly, closing at $12.23, with institutional investors holding 70.9% of shares. Weiss Ratings将库存降为“销售”,但分析师维持了“中价购买”共识,目标为21美元。 Weiss Ratings downgraded the stock to “sell,” but analysts maintain a “moderate buy” consensus with a $21 target.